替奈普酶用于急性非大血管闭塞性缺血性卒中发病4.5至24小时:OPTION随机临床试验
OPTION试验在中国48个中心纳入566例非大血管闭塞性急性缺血性卒中且灌注成像显示存在可挽救脑组织的患者,随机接受静脉替奈普酶0.25 mg/kg(最大25 mg)或标准药物治疗。替奈普酶组90天极佳功能预后(改良Rankin量表0-1分)为43.6%,对照组为34.2%(风险比1.28,95%CI 1.04-1.57,P=0.02)。替奈普酶组36小时内症状性颅内出血发生率为2.8%,对照组为0%(风险差2.85%,95%CI 1.16%-5.54%,P=0.004);90天死亡率分别为5.0%和3.2%(风险比1.57,95%CI 0.69-3.57,P=0.28)。
要点
- 发病4.5至24小时的非大血管闭塞性缺血性卒中且灌注成像显示可挽救脑组织者,替奈普酶组90天改良Rankin量表0-1分比例43.6% vs 对照组34.2%(风险比1.28,95%CI 1.04-1.57,P=0.02)
- 替奈普酶组36小时内症状性颅内出血发生率2.8%,对照组0%(风险差2.85%,95%CI 1.16%-5.54%,P=0.004)
- 替奈普酶组90天死亡率5.0%,对照组3.2%(风险比1.57,95%CI 0.69-3.57,P=0.28),未达统计学显著
- 替奈普酶剂量为0.25 mg/kg静脉给药,最大剂量25 mg,用于发病4.5至24小时经灌注成像筛选的非大血管闭塞患者
- 该试验为随机、开放标签、盲法终点设计,在中国48个中心开展,共566例纳入主要分析
适用人群与场景
- 发病4.5至24小时(自最后正常时间起算)的非大血管闭塞性急性缺血性卒中患者,且灌注成像显示存在可挽救脑组织
- 年龄中位数68岁(IQR 59-75),女性196例(34.6%)
诊断标准与关键阈值
- 非大血管闭塞性缺血性卒中,经灌注成像确定存在可挽救脑组织,发病时间在4.5至24小时之间
处置流程与药物剂量
- 替奈普酶0.25 mg/kg静脉给药,最大剂量25 mg
红旗征与不能漏的情况
- 症状性颅内出血:替奈普酶组36小时内发生率2.8%,对照组0%
研究设计与关键结果
- 随机、开放标签、盲法终点临床试验,中国48个中心,566例纳入主要分析(替奈普酶组282例,对照组284例)
- 主要疗效终点90天极佳功能预后(改良Rankin量表0-1分):替奈普酶组43.6%(123/282) vs 对照组34.2%(97/284),风险比1.28(95%CI 1.04-1.57),P=0.02
- 安全性终点36小时内症状性颅内出血:替奈普酶组2.8% vs 对照组0%,风险差2.85%(95%CI 1.16%-5.54%),P=0.004
- 90天死亡率:替奈普酶组5.0% vs 对照组3.2%,风险比1.57(95%CI 0.69-3.57),P=0.28
证据类型、等级与局限
- 证据类型:随机、开放标签、盲法终点临床试验
- 局限:原文未报告局限性
对床旁实践的改变
- 对于发病4.5至24小时的非大血管闭塞性缺血性卒中且灌注成像显示可挽救脑组织的患者,静脉替奈普酶0.25 mg/kg(最大25 mg)较标准治疗提高90天极佳功能预后,但症状性颅内出血风险增加,作者结论为替奈普酶带来更高的极佳功能预后可能性但增加症状性颅内出血风险
指南或共识出处
- OPTION随机临床试验(ClinicalTrials.gov标识NCT05752916)
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The efficacy and safety of intravenous tenecteplase in non-large vessel occlusion acute ischemic stroke beyond 4.5 hours after symptom onset remain uncertain.
OBJECTIVE: To assess the efficacy and safety of intravenous tenecteplase administered 4.5 to 24 hours after stroke onset in patients with non-large vessel occlusion and salvageable brain tissue.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, blinded end-point clinical trial was conducted at 48 centers in China. A total of 566 patients with non-large vessel occlusion stroke and evidence of potentially salvageable tissue determined on perfusion imaging presenting within 4.5 to 24 hours of the time last seen well were recruited between June 2, 2023, and August 4, 2025 (final follow-up, October 28, 2025).
INTERVENTIONS: Patients were randomly assigned 1:1 using a minimization algorithm to receive intravenous tenecteplase (0.25 mg/kg; maximum dose, 25 mg; n = 282) or standard medical treatment (n = 284).
MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale at 90 days. Safety outcomes included symptomatic intracranial hemorrhage within 36 hours and mortality within 90 days.
RESULTS: Among the 570 patients randomized, 566 were included in the primary analysis (median age, 68 [IQR, 59-75] years; 196 female [34.6%]). An excellent functional outcome was observed in 123 of 282 patients (43.6%) in the tenecteplase group and 97 of 284 (34.2%) in the control group (risk ratio, 1.28 [95% CI, 1.04-1.57]; P = .02). The incidence of symptomatic intracranial hemorrhage at 2.8% was higher with tenecteplase than with standard medical treatment at 0% (risk difference, 2.85% [95% CI, 1.16%-5.54%]; P = .004), and the mortality at 90 days was 5.0% and 3.2%, respectively (risk ratio, 1.57 [95% CI, 0.69-3.57]; P = .28).
CONCLUSIONS AND RELEVANCE: Among patients with non-large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase administered 4.5 to 24 hours after onset resulted in a greater likelihood of an excellent functional outcome at 90 days than standard care but had an increased risk of symptomatic intracranial hemorrhage.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05752916.
参考来源
- Ma G, Mo R, Zuo Y, et al. Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial. JAMA. 2026. PMID: 41642827. doi:10.1001/jama.2026.0210
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。